Cargando…

Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children

OBJECTIVE: To study and compare the clinical effects of azithromycin and erythromycin on children with mycoplasma pneumonia. METHODS: Total 132 children with mycoplasma pneumonia who were admitted to our hospital between November 2017 and September 2018 were selected as the research subjects. All th...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Rui, Yu, Qianqian, Zhang, Guohui, Li, Baoqiang, Han, Shuzhen, Li, Guiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994860/
https://www.ncbi.nlm.nih.gov/pubmed/32063951
http://dx.doi.org/10.12669/pjms.36.2.1441
_version_ 1783493270136946688
author Han, Rui
Yu, Qianqian
Zhang, Guohui
Li, Baoqiang
Han, Shuzhen
Li, Guiying
author_facet Han, Rui
Yu, Qianqian
Zhang, Guohui
Li, Baoqiang
Han, Shuzhen
Li, Guiying
author_sort Han, Rui
collection PubMed
description OBJECTIVE: To study and compare the clinical effects of azithromycin and erythromycin on children with mycoplasma pneumonia. METHODS: Total 132 children with mycoplasma pneumonia who were admitted to our hospital between November 2017 and September 2018 were selected as the research subjects. All the children were divided into an observation group and a control group according to random number table, 66 each. The observation group was treated with azithromycin, while the control group was treated with erythromycin. The therapeutic effect, incidence of adverse reactions and disappearance time of clinical symptoms were compared between the two groups. RESULTS: The total efficacy of the observation group was 98.04%, and that of the control group was 74.51%; there was a significant difference (X(2)=7.184, P=0.007). The incidence of adverse reactions in the observation group was 15.69%, significantly lower than that in the control group (41.18%) (X(2)=6.376, P=0.002). The disappearance of fever, cough, rale and X ray shadow of the observation group was significantly earlier than that of the control group, and the difference was statistically significant (P<0.05). CONCLUSION: Compared with erythromycin, azithromycin is more effective in the treatment of mycoplasma pneumonia in children. Azithromycin can further shorten the improvement time of clinical symptoms and signs and has few adverse reactions and high safety. It is worth clinical application.
format Online
Article
Text
id pubmed-6994860
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-69948602020-02-14 Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children Han, Rui Yu, Qianqian Zhang, Guohui Li, Baoqiang Han, Shuzhen Li, Guiying Pak J Med Sci Original Article OBJECTIVE: To study and compare the clinical effects of azithromycin and erythromycin on children with mycoplasma pneumonia. METHODS: Total 132 children with mycoplasma pneumonia who were admitted to our hospital between November 2017 and September 2018 were selected as the research subjects. All the children were divided into an observation group and a control group according to random number table, 66 each. The observation group was treated with azithromycin, while the control group was treated with erythromycin. The therapeutic effect, incidence of adverse reactions and disappearance time of clinical symptoms were compared between the two groups. RESULTS: The total efficacy of the observation group was 98.04%, and that of the control group was 74.51%; there was a significant difference (X(2)=7.184, P=0.007). The incidence of adverse reactions in the observation group was 15.69%, significantly lower than that in the control group (41.18%) (X(2)=6.376, P=0.002). The disappearance of fever, cough, rale and X ray shadow of the observation group was significantly earlier than that of the control group, and the difference was statistically significant (P<0.05). CONCLUSION: Compared with erythromycin, azithromycin is more effective in the treatment of mycoplasma pneumonia in children. Azithromycin can further shorten the improvement time of clinical symptoms and signs and has few adverse reactions and high safety. It is worth clinical application. Professional Medical Publications 2020 /pmc/articles/PMC6994860/ /pubmed/32063951 http://dx.doi.org/10.12669/pjms.36.2.1441 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Han, Rui
Yu, Qianqian
Zhang, Guohui
Li, Baoqiang
Han, Shuzhen
Li, Guiying
Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
title Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
title_full Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
title_fullStr Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
title_full_unstemmed Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
title_short Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
title_sort comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994860/
https://www.ncbi.nlm.nih.gov/pubmed/32063951
http://dx.doi.org/10.12669/pjms.36.2.1441
work_keys_str_mv AT hanrui comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren
AT yuqianqian comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren
AT zhangguohui comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren
AT libaoqiang comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren
AT hanshuzhen comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren
AT liguiying comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren